INTRODUCTION
Diabetic retinopathy (DR), and subsequent diabetic macular edema (DME), is the leading cause of blindness among working-aged adults. [1] [2] [3] Additionally, while diabetes prevalence continues to rise, 4-6 the prevalence of DR/DME has also increased. Presently, four pharmacotherapies, including anti-vascular endothelial growth factor (VEGF) agents and corticosteroids, are approved for treatment of DME. [7] [8] [9] [10] In the phase 3 RIDE/RISE trials of ranibizumab (Lucentis; Genentech, South San Francisco, CA) in DME, 33.6% (RIDE) and 44.8% (RISE) of patients who received ranibizumab (0.3 mg) gained 3 or more lines of Early Treatment Diabetic Retinopathy Study best-corrected visual acuity with monthly injections; however, some patients either did not respond or responded inadequately. 11 Further, 40.8% (RIDE) and 37.6% (RISE) of patients experienced fewer than 10 letters of improvement, and 14.4% (RIDE) and 15.2% (RISE) experienced no improvement or loss of vision at the primary endpoint. 11 A post-hoc analysis of the Diabetic Retinopathy Clinical Research Network (DRCR. net) Protocol I trial reported that anti-VEGF response can be categorized as early and consistent, early but inconsistent, slow and variable, or no response, with approximately 50% of patients falling into the latter three categories. 12 Moreover, patients with DME in clinical practice receive far fewer injections than patients in clinical trials. A retrospective analysis of a commercial payer claims database that examined data between 2008 and 2010 reported an average of three bevacizumab (Avastin; Genentech, South San Francisco, CA) injections per year in patients with DME. 13 The present study had two goals. First, DME treatment frequency during a 3-year period was determined by analyzing billing of anti-VEGF treatments in a sample of Medicare enrollees. Second, patterns of treatment usage were determined by investigating the timing of last anti-VEGF treatments compared with timing of last DME diagnosis during the 3-year period.
PATIENTS AND METHODS

Data Source
The Medicare Standard Analytic Files (SAFs; includes medical claims submitted for laboratory tests, inpatient hospital stays, outpatient care, physician care, skilled nursing facility care, home health care, durable medical equipment use, and hospice care, as well as a denominator file that includes beneficiaries' demographic characteristics [age, sex, race, etc.] and vital status recorded with the date of death, if applicable) provided by the Centers for Medicare and Medicaid Services were analyzed. The SAFs contain every fully adjudicated Medicare claim filed for 5% of the Medicare population, which includes U.S. citizens ages 65 years and older, those younger than 65 years with certain disabilities or illnesses, and/or those with kidney failure requiring dialysis or kidney transplant.
14 Beneficiaries who are also enrolled in a managed-care organization were excluded. Beneficiary identities were encrypted but were consistent between all claims in a given year and across years, allowing for longitudinal analysis. Claim dates prior to 2009 were encrypted to the year and quarter. Weekly data submissions to the National Claims History 100% Nearline File were used to construct the SAFs database. This analysis used observational data from patients associated with the Medicare SAFs between 2007 and 2013.
Study Sample
The analyzed cohort consisted of patients who were diagnosed with DME between 2008 and 2010 (Part B or Outpatient Claim) and who received an anti-VEGF treatment for DME. Patients were included if they were enrolled in Medicare for 1 year prior to and 3 years following their first DME diagnosis. Patients who received an anti-VEGF treatment within 1 year prior to first DME diagnosis were excluded ( Figure 1 ). Diagnosis and procedure codes are defined in Table 1 . Although submission of an anti-VEGF for DME claim was required, claims for intravitreal triamcinolone acetonide (IVTA) and laser treatment were also reported to gain insight into adjunctive therapy required.
Observation Period
The observation period for each enrolled patient was defined as the 12 consecutive quarters (3 years) following the quarter in which the patient received his or her first anti-VEGF treatment for DME.
Statistical Methods
A Kruskal-Wallis nonparametric analysis of variance was used to compare quantitative data (eg, number of claims per patient) across groups such as yearly cohorts, and a Chi-square test for goodness of fit was used to compare percentages or proportions across time periods such as years or quarters. Calculations were performed using NCSS 10 (NCSS, Kaysville, UT) or StatXact 10 (Cytel, Cambridge, MA) statistical software. Figure 3 (A-B) . Quarterly analysis of final diabetic macular edema (DME) diagnosis and final anti-vascular endothelial growth factor (VEGF) treatment for DME. (A) Quarter of last DME diagnosis. (B) Quarter of last anti-VEGF treatment for DME.
Figure 3 (C-D).
Quarterly analysis of final diabetic macular edema (DME) diagnosis and final anti-vascular endothelial growth factor treatment for DME. (C) Quarter of last intravitreal triamcinolone acetonide treatment for DME. (D) Quarter of last laser treatment for DME. a P < .001 by Chi-square goodness-of-fit test. b P = .008 across all of the quarters, but P = .11 if Q1 was removed; both by Chi-square goodness-of-fit test. 
RESULTS
Baseline Characteristics
The study cohort included 772 patients (mean age: 70 years). Most patients (76%) were white, and the cohort was well-balanced with regard to sex ( Table 2) . Patient enrollment steadily increased each year during the study period. Table 3 provides a DME treatment frequency analysis for the overall study period. All patients were required to have submitted an anti-VEGF treatment claim, and among these patients, 19% and 34% submitted IVTA and laser treatment claims, respectively. An average of 4.2, 2.4, and 2.4 anti-VEGF, IVTA, and laser treatment claims per patient, respectively, were submitted.
Claims for DME Treatment During the Study
The yearly DME treatment frequency analysis is shown in Table 4 Figure 2A displays the years in which patients received their final DME diagnosis. This analysis revealed that 46% of patients received their final DME diagnosis within the first year, whereas a significant proportion (54%) received their final DME diagnosis in years 2 or 3 (P = .03). Importantly, despite increased patient enrollment each year, patterns of final DME diagnosis decreased dramatically at year 2 (17.7%) and then increased at year 3 (36.1%), but not to the level of year 1 (P < .001). This supported the overall study period data.
DME Duration During the Study
DME Treatment Patterns
Yearly analysis of final anti-VEGF treatment for DME is displayed in Figure 2B . Within 1 year of diagnosis, 65% of patients received their final anti-VEGF treatment for DME; the remaining 35% continued to receive anti-VEGF treatments throughout the study (P < .001). Patients who received their final DME diagnosis in years 1, 2, or 3 submitted a mean of 1.9, 4, or 7.2 anti-VEGF claims, respectively, which differed significantly among the cohorts (P < .001 by Kruskal-Wallis).
As shown in Figure 2C , 45% of patients received their final IVTA treatment for DME within the first year following DME diagnosis. However, during years 2 and 3, a numerically greater proportion of patients continued to receive IVTA treatments compared with those who continued to receive VEGF inhibitors (55% vs 35%; P = .22 by Chi-square goodness-of-fit test) ( Figures  2B and 2C) .
Similar to the anti-VEGF analysis, a higher proportion of patients received their final laser treatment for DME in the first year of the study (55%) compared with patients who continued to receive laser treatments through years 2 and 3; however, the difference was not significant. (45%; P = .11 by Chi-square goodness-offit test) ( Figure 2D) . A quarterly analysis of final DME diagnosis and treatment for DME was performed, and the trend was similar to the yearly analysis ( Figures  3A and 3D ).
To gain a more-detailed insight into the course of the disease, patients were grouped by the year in which they received their final DME diagnosis and further categorized based on the number of quarters in which a DME claim was submitted. Patients who received their final DME diagnosis in year 1 had the fewest quarters (mean ± standard deviation [SD]: 1.7 ± 0.9) with a DME claim submitted. Patients who received their final DME diagnosis in years 2 or 3 had more quarters (mean ± SD: 4.3 ± 1.5 and 7.2 ± 2.9, respectively) with a DME claim submitted (P < .001 by Kruskal-Wallis test). Furthermore, more than 70% of patients who received their final DME diagnosis in year 1 submitted a claim for DME in the first quarter following diagnosis.
DISCUSSION
The current analysis demonstrated that although the number of anti-VEGF treatments increased during the specified time period, the investigated cohort was undertreated compared with cohorts examined in pivotal clinical trials. 15, 16 The results of this analysis -the first Medicare claims analysis to examine therapy patterns in a subset of DME patients -is consistent with the results of a larger commercial payer database analysis conducted during the same time period. 13 The commercial database study, which included cohorts of patients newly diagnosed with DME in years 2008 to 2010 (n = 2,733), reported that the yearly mean numbers of bevacizumab injections were 2.2, 2.5, and 3.6 in years 2008, 2009, and 2010, respectively. 13 Anti-VEGF usage patterns in this study suggested that DME is a multifactorial disease, with 65% of DME persisting longer than a year. Similarly, a posthoc analysis of the DRCR.net Protocol I trial showed that among ranibizumab-treated patients, 50% could be classified as complete responders based on changes in macular thickness after four monthly injections. 12 The remaining 50% of patients did not achieve the same anatomical response after four monthly injections and had inconsistent improvement, slow improvement, or no improvement after 1 year of treatment based on visual acuity outcomes. Although cross-study comparisons cannot be made, particularly since the current analysis did not investigate macular thickness, this categorical classification of patients with DME is consistent with the current analysis, given that 54% of patients received their final DME diagnosis in years 2 or 3. Patients with bilateral DME may experience varying degrees of disease duration and/ or severity between their eyes. In the current study, 64% of patients with DME in year 1 do not report any DME in year 3. Also, 62% of patients with DME in both eyes at year 1 and who continue to report DME in year 3, reported DME in both eyes at year 3. Further, 27% of patients with DME in both eyes at year 1 reported DME in 1 eye in year 3. Overall, less than 2% of patients experienced a transition from DME in 1 eye to the fellow eye between years 1 and 3.
In patients for whom anti-VEGF therapy is effective, an effect is generally observed shortly after initiation of treatment. Among patients who received their final DME diagnosis in year 1, more than 70% submitted their final anti-VEGF claim in the first quarter following diagnosis. In addition to the required anti-VEGF treatment for DME, 19% and 34% of patients in this study submitted a claim for IVTA or laser treatment for DME, respectively, suggesting that, in addition to anti-VEGF therapy, these patients required additional intervention to improve their vision. Presently, two anti-VEGF and two corticosteroid therapies are approved for the treatment of DME; however, corticosteroids, rather than anti-VEGF therapy, broadly target an array of angiogenic and inflammatory cytokines. [7] [8] [9] [10] 17 If a response to anti-VEGF therapy is not apparent after multiple monthly injections, it is possible that patients may benefit from an alternative treatment, such as corticosteroids.
Interpretations regarding treatment administration frequency and practices must be made cautiously. The treatment landscape for DME at present differs from that of the time in which this study was initiated. The pharmacotherapies analyzed in the current report, VEGF inhibitors and IVTA, were not U.S. Food and Drug Administration (FDA)-approved when these patients were diagnosed with DME. It is possible that a lack of FDA approval may have influenced treatment decisions because of reimbursement practices. Ranibizumab was not FDA-approved for the treatment of DME until 2012, 18 and results from the landmark RISE/RIDE trials were not published until 2013. 15 Therefore, conclusions from the current data set are based on off-label use of this therapy during a time in which optimal treatment frequency may not have been fully realized.
The present report had a number of technical limitations. First, this analysis had a smaller sample size than the previous commercial payer database study. 13 Additionally, data are based on a 3-year analysis, and this time point encompassed patients who received their final DME diagnosis in year 3, as well as those who did not receive their final DME diagnosis during the study period. Finally, results were based on the assumption that once a DME diagnosis is no longer documented, the DME is resolved. Nevertheless, the current report and the commercial payer claims database analysis found that patients in routine clinical practice received far fewer monthly injections than what was given in many of the clinical trials for DME. 15, 16 This Medicare claims analysis was the first such analysis of a payer claims database assessing persistence of DME diagnosis and demonstrated that patients are undertreated with VEGF inhibitors compared with what has been seen in landmark studies. Additionally, persistent DME is a problematic issue for a sizable proportion of patients with this disease, and alternative treatment strategies may be relevant for these patients. 
